Our complete list of publications

• 2026
  Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity

  Chung J*, Vallurupalli M*, Noel S, Schor G, Mrowka S, Scapozza I, Demere Z, Kammula SV, Hu M, … Yates KB, Golub TR, Manguso RT

  Science 392(6794):eady5196 Co-first author DOI
• 2025
  Generative design of cell type-specific RNA splicing elements for programmable gene regulation

  Chen XD*, Jim M*, Vallurupalli M*, Cao K*, Torres AN, … Schor G, Mrowka S, Hu M, Golub T, Chen F

  bioRxiv Preprint Co-first author DOI
• 2025
  O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis

  Misek SA, Borgenvik A, Christen D, Kyrila G, Zhang A, … Vallurupalli M, … Beroukhim R, Brummer T, Halim A, Bandopadhayay P

  bioRxiv Preprint DOI
• 2024
  Helicase-assisted continuous editing for programmable mutagenesis of endogenous genomes

  Chen XD, Chen Z, Wythes G, Zhang Y, Orr BC, Sun G, Thao K, Vallurupalli M, … Bernstein BE, Chen F

  Science 386(6718):eadn5876 DOI
• 2023
  Understanding inequities in precision oncology diagnostics

  Dutta R*, Vallurupalli M*, McVeigh Q, Huang FW, Rebbeck TR

  Nature Cancer Co-first author DOI
• 2021
  Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML

  Tothova Z, Valton AL, Gorelov RA, Vallurupalli M, Krill-Burger JM, … Dekker J, Ebert BL

  JCI Insight 6(3):e142149 DOI
• 2021
  Global precision oncology: a call to action on expanding access to targeted cancer therapies

  Bharadwaj M*, Vallurupalli M*, Huang FW

  The Oncologist 26(5):353–355 Co-first author DOI
• 2020
  Effects of interleukin-1β inhibition on incident anemia: exploratory analyses from a randomized trial

  Vallurupalli M, MacFadyen JG, Glynn RJ, Thuren T, Libby P, Berliner N, Ridker PM

  Annals of Internal Medicine 172(8):523–532 First author DOI
• 2019
  Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis

  Vallurupalli M, Berliner N

  Blood 134(21):1783–1786 First author DOI
• 2015
  Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma

  Kennedy AL*, Vallurupalli M*, Chen L*, Crompton B, … Stegmaier K

  Oncotarget 6(30):30178–30193 Co-first author DOI
• 2013
  Mourning on morning rounds

  Vallurupalli M

  New England Journal of Medicine 369(5):404–405 DOI

* Co-first author (equal contribution). Names in orange are lab trainees.